08.18.25 -- Commercial Clarity And Communication Will Define The Future Of CGT CDMOs

The first in a two-part series focuses on the initial stages of product development — specifically, how to move from candidate selection to a Phase 1 IND application.

Pharma leaders discuss advancing equity through inclusive trial design, access planning, and global partnerships to overcome persistent health disparities and expand access to lifesaving therapies worldwide.

Discover how one family defied the odds—bringing a lifesaving gene therapy from idea to treatment in just 14 months after a devastating rare disease diagnosis.

By leveraging cells equipped with an existing TARGATT™ landing pad, we demonstrate how inducible expression can be efficiently achieved within just 4-6 weeks after donor plasmid creation.

Observe how streamlined, scalable platforms are transforming viral vector manufacturing to accelerate the delivery of cell and gene therapies to patients.

Uncover how a Design of Experiment (DoE) model was developed to address the multifactorial nature of large-scale transfection, where variables like viable cell density (VCD) and DNA amount jointly influence efficiency.

Learn how predictive models can monitor key CQAs, such as RNA concentration and nucleoside triphosphate consumption, and explore RBP and MIT’s vision for revolutionizing biomanufacturing.

Accelerate cell and gene therapy development with high-yield, regulatory-compliant plasmid DNA manufacturing that shortens timelines, minimizes risks, and streamlines your supply chain.

Explore specificities and challenges, leveraging automation for scalability with the Cocoon^® Platform, and building a vein-to-vein network to achieve ‘just-in-time’ delivery of therapies.